TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03066115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: See arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: See arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: See arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: See arm description.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous Catheter
Description: Two intravenous catheters will be placed for each study visit. One catheter will be used for the intravenous infusion of study drugs (L-NMMA, Ketorolac, and Ascorbic Acid). The second catheter will be used to draw intermittent blood samples at 8-specific time points throughout each study visit to ensure pharmaceutical efficacy and examine systemic physiologic blood variables of interest.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous Catheter
Description: Two intravenous catheters will be placed for each study visit. One catheter will be used for the intravenous infusion of study drugs (L-NMMA, Ketorolac, and Ascorbic Acid). The second catheter will be used to draw intermittent blood samples at 8-specific time points throughout each study visit to ensure pharmaceutical efficacy and examine systemic physiologic blood variables of interest.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler Ultrasound
Description: MCAv will be measured via the transtemporal window while BAv will be measured through the transforaminal window with 2-MHz transcranial Doppler ultrasound probes (TCD, Neurovision model 500M, Multigon Industries, Inc.; Yonkers, NY, USA)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler Ultrasound
Description: MCAv will be measured via the transtemporal window while BAv will be measured through the transforaminal window with 2-MHz transcranial Doppler ultrasound probes (TCD, Neurovision model 500M, Multigon Industries, Inc.; Yonkers, NY, USA)
Study: NCT03609008

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levcromakalim
Description: Intravenous administration of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cerebral hemodynamic in healthy volunteers.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intravenous administration of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cerebral hemodynamic in healthy volunteers.
Study: NCT03837431

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin slit
Description: Skin slit microscopy, RDT and PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Dental broach
Description: Dental broach RDT and PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Tape disc
Description: Tape disc PCR
Study: NCT00738023

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: Diabetic subjects will be receive rosiglitazone for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline 0.9%
Description: Normal saline 0.9% intravenous infusion at 40ml/hr for 48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid 20%
Description: Intralipid 20% at 40ml/hr intravenously for 48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid 20%
Description: Intralipid 20% at 40ml/hr intravenously for 48 hours
Study: NCT00536341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: 2.5 mg orally (PO) daily, Days 8-28, Cycle 1; 5.0 mg PO daily, Days 8-28 Cycles 2-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 Cycle 1 (split over Day 1 \& Day 2); 500 mg/m2 Day 1 of Cycles 2-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m2 on Days 1, 2, and 3
Study: NCT04115683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual Task Training
Description: 45 minutes of dual task training consisting of motor activities (walking, balance... etc.) with combination of cognitive activities (spelling words, image description, nomination, word generation, counting... etc.) at sime time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single Task Training
Description: 45 minutes of single task training consisting of same motor activities (walking, balance... etc.)
Study: NCT01839175

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeisVac-C
Description: 0.5 mL intramuscular injection at 2 and 4 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar 13
Description: 0.5 mL intramuscular injection at 2 and 4 months of age (primary series) 0.5 mL intramuscular injection at 13 months of age (booster)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13
Description: 0.5 mL intramuscular injection at 2 and 4 months of age (primary series) 0.5 mL intramuscular injection at 13 months of age (booster)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RotaTeq
Description: 2 mL oral administration at 2, 3 and 4 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RotaTeq
Description: 2 mL oral administration at 2, 3 and 4 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimenrix
Description: 0.5 mL intramuscular injection at 12 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nimenrix
Description: 0.5 mL intramuscular injection at 12 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-M-RVAXPRO
Description: 0.5 mL intramuscular or subcutaneous injection at 13 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-M-RVAXPRO
Description: 0.5 mL intramuscular or subcutaneous injection at 13 months of age
Study: NCT02614287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC
Study: NCT03435770

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUSRA RFA needle
Description: A 19-gauge RFA electrode and a RF generator with a electrode that is needle-shaped and echogenic that allows EUS guided puncture of the target lesion. The active electrode tip is 1 cm in length. During ablation, the RF electrode is cooled and perfused internally with circulating chilled saline solution (0°C) delivered via a pump to maintain a constant temperature. A setting of 50W energy would be used for RFA and the duration of application is 10 seconds. Sequential applications of up to 7 times per session are allowed for complete ablation of the lesions.
Study: NCT02020252

Intervention type: BEHAVIORAL
Intervention: Testing an interactive technology in a diverse health literary population
Description: Enrollment in therapeutic cancer trials remains low, and is especially challenging for patients with low health literacy. We tested an interactive technology designed for patients with diverse health literacy skills aimed at improving patient receptiveness, willingness, knowledge, self-efficacy and positive attitudes regarding clinical trials.
Study: NCT04585412

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron
Description: Pharmacokinetic study under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Pharmacokinetic study under fasting conditions
Study: NCT04292132

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement
Description: interforaminal placement of 2 implants

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant placement
Description: interforaminal placement of 2 implants

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate loading
Description: immediate loading with a locator retained mandibular overdenture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional loading
Description: conventional loading with a locator retained mandibular overdenture 3 months postoperatively
Study: NCT01215344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VELCADE
Description: 1.3 mg/m2 by IV on days 1, 4, 8, 11 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VELCADE
Description: 1.3 mg/m2 by IV on days 1, 4, 8, 11 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg by mouth on days 1-4 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg the day before and the day after receiving VELCADE

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DVT prophylaxis
Description: At least one asprin 81 mg per day. Other option per physician's choice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DVT prophylaxis
Description: At least one asprin 81 mg per day. Other option per physician's choice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Description: Zoledronic acid by IB or pamidronate by IV can be used as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin
Description: 30 mg/m2 on day 4 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg by mouth on days 1-4, 8-11, and 15-18 of cycle 1 and days 1-4 on cycle 2-4
Study: NCT01459094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B (CANA/MET IR FDC tablet - fed state) / A (CANA/MET IR FDC tablet - fasting state)
Description: Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fed state on Day 1 of Treatment Period 1 followed 10-14 days later by Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fasting state on Day 1 of Treatment Period 2.
Study: NCT03950635

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Consume whole-foods, fiber-rich diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Consume high fat, low carbohydrate (ketogenic) diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00087217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT04683705

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: 1. High-resolution ultrasound evaluation of the shoulder region to recognize the biceps tendon, subscapularis tendon, supraspinatus tendon, and infraspinatus tendon.~2. High-resolution ultrasound evaluation for the C5, C6 and C7 nerve roots and the suprascapular nerve over the supraclavicular fossa , in the supraspinatus fossa and in the infraspinatus fossa to obtain the nerve cross-sectional image.~3. Collecting the shoulder pain-related information, including physical examination results (bicipital groove tenderness, Speed test, Yergason's test, Empty can test, Neer test, Hawkins-Kennedy test and painful arc test) and status of disability using Shoulder Pain and Disability Index (SPADI).

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: 1. High-resolution ultrasound evaluation of the shoulder region to recognize the biceps tendon, subscapularis tendon, supraspinatus tendon, and infraspinatus tendon.~2. High-resolution ultrasound evaluation for the C5, C6 and C7 nerve roots and the suprascapular nerve over the supraclavicular fossa , in the supraspinatus fossa and in the infraspinatus fossa to obtain the nerve cross-sectional image.~3. Collecting the shoulder pain-related information, including physical examination results (bicipital groove tenderness, Speed test, Yergason's test, Empty can test, Neer test, Hawkins-Kennedy test and painful arc test) and status of disability using Shoulder Pain and Disability Index (SPADI).
Study: NCT00628381

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-citrulline supplementation
Description: L-citrulline, 1.8micromol/kg/min, during 8 hours continuously supplemented

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-alanine
Description: L-alanine enteral infusion, isocaloric dosage (3.6 micromol/kg/min), during 8 hours, continuously supplemented
Study: NCT04582006

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Surgical treatment of morbid obesity.

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Surgical treatment of morbid obesity.
Study: NCT04162106

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smoke management during laparoscopic cholecystectomy using the Ultravision™ System
Description: The Ultravision™ System will be used during the procedure to manage smoke generated as a result of the use of diathermy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smoke management during laparoscopic cholecystectomy using the Airseal® iFS
Description: The Airseal® iFS will be used during the procedure to manage smoke generated as a result of the use of diathermy.
Study: NCT01302002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Pre-Surgery
Description: 500 mg tablet, taken twice a day for 3 weeks
Study: NCT04427293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 12mg daily for 7 days prior to surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV on day 1
Study: NCT05018364

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum erythropoietin level
Description: Evaluate serum erythropoietin level in neonates exposed to hypoxia compared to control group

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum erythropoietin level
Description: Evaluate serum erythropoietin level in neonates exposed to hypoxia compared to control group
Study: NCT02987582

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion-focused mindfulness group
Description: Intervention The group will run for 8-weeks. Each group session is 2 and a half hours. Half way through the intervention there will be a 5 hour retreat on the weekend. A typical group format includes 20-40 minutes of meditation, followed by 10 minutes of independent journaling. Then group members will have time to report on recollections from meditation and facilitators will provide feedback. There is a break and the second part of the group focuses on a didactic teaching topic. Topics change each week; groups will run between October 2016 and June 2018.
Study: NCT01101607

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal Forearm Fracture Reduction
Description: Fracture reduction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal Forearm Fracture Reduction
Description: Fracture reduction
Study: NCT02539550

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06266047
Description: PF-06266047
Study: NCT00255099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TMC125
Description: 2 x 100 mg tablets b.i.d. / 96 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets b.i.d. / 96 weeks
Study: NCT04345497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes-Specific Formula
Description: Diabetes-Specific Formula and Standard of Care

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Of Care
Description: Standard of Care
Study: NCT03372603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745
Description: GSK2798745 tablets will be available as white to almost white, round, film-coated tablets (micronized active pharmaceutical ingredient \[API\]) to be taken with a glass of water (approximately 240 mL).
Study: NCT02325037

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo multiple doses
Description: Multiple doses, daily for 14 days, oral suspension, matching placebo
Study: NCT03372603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745
Description: GSK2798745 tablets will be available as white to almost white, round, film-coated tablets (micronized active pharmaceutical ingredient \[API\]) to be taken with a glass of water (approximately 240 mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets will be available as white to almost white, round, film-coated tablets to be taken with a glass of water (approximately 240 mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets will be available as white to almost white, round, film-coated tablets to be taken with a glass of water (approximately 240 mL).
Study: NCT02747147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIVA blood collection device
Description: the device is attached to a peripheral IV catheter for use as a direct blood draw device into a vacuum tube or a syringe
Study: NCT02867462

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: standard care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manipulator consultation radiotherapy added to standard care
Study: NCT02639065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg IV every 4 weeks (1 cycle) for a maximum 13 doses (12 months), or until unacceptable toxicities or disease recurrence.
Study: NCT04523220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1213790 (Osocimab)
Description: Single loading dose as subcutaneous abdominal injection followed by monthly maintenance doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1213790 (Osocimab)
Description: Single loading dose as subcutaneous abdominal injection followed by monthly maintenance doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous administration in the same manner as Osocimab.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous administration in the same manner as Osocimab.
Study: NCT04638257

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacilli rhamnosus GR-1 and Lactobacilli fermentum RC-14
Description: Daily oral Lactobacilli starting at =\<18 weeks of gestation in singleton pregnancy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral placebo starting at =\<18 weeks of gestation in singleton pregnancy
Study: NCT02011971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinpocetine
Description: Vinpocetine is a chemical obtained from the leaves of the Lesser Periwinkle. It has been shown to improve cerebral metabolism and memory in animals and humans. In addition, it has been shown to enhance long-term potentiation, which has been linked to memory mechanisms. Furthermore, vinpocetine has been shown to have anticonvulsant effects and is more potent than several commonly used antiepileptic drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinpocetine
Description: Vinpocetine is a chemical obtained from the leaves of the Lesser Periwinkle. It has been shown to improve cerebral metabolism and memory in animals and humans. In addition, it has been shown to enhance long-term potentiation, which has been linked to memory mechanisms. Furthermore, vinpocetine has been shown to have anticonvulsant effects and is more potent than several commonly used antiepileptic drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinpocetine
Description: Vinpocetine is a chemical obtained from the leaves of the Lesser Periwinkle. It has been shown to improve cerebral metabolism and memory in animals and humans. In addition, it has been shown to enhance long-term potentiation, which has been linked to memory mechanisms. Furthermore, vinpocetine has been shown to have anticonvulsant effects and is more potent than several commonly used antiepileptic drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vinpocetine
Description: Vinpocetine is a chemical obtained from the leaves of the Lesser Periwinkle. It has been shown to improve cerebral metabolism and memory in animals and humans. In addition, it has been shown to enhance long-term potentiation, which has been linked to memory mechanisms. Furthermore, vinpocetine has been shown to have anticonvulsant effects and is more potent than several commonly used antiepileptic drug
Study: NCT02605824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: n-acetylcystine
Description: NAC is a mucolytic drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: Normal saline is a placebo agent.
Study: NCT01989897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saline with 1mg/ml Histamine base

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diluent, saline with HSA--phenol
Study: NCT02007304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eccentric exercise training
Description: 12 weeks of lower leg eccentric training
Study: NCT02592252

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participatory gender training
Description: 10 sessions of participatory gender training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participatory gender training
Description: 10 sessions of participatory gender training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microfinance
Description: Microfinance loan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microfinance
Description: Microfinance loan
Study: NCT04650711

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: p16 protein expression
Description: P16INK4A immunohistochemical staining is to be performed in residual cytology samples.
Study: NCT00636558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVA21
Description: IV infusion, dose escalation of one or two infusions of escalating strength
Study: NCT00873015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium nitrite
Description: 14 day continuous infusion of one of 3 escalating doses of sodium nitrite: 32 nmol/min/kg, 48 nmol/min/kg, or 64 nmol/min/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 14 day continuous infusion of a vehicle control infusion